Instructions for Ingavirin
Dosage form Ingavirin:
Capsules No. 2 or No. 4 of blue color (for a dosage of 30 mg), capsules No. 2 or No. 3 of red color (for a dosage of 90 mg). The capsule lid is marked with a white logo in the form of a ring and the letter AND inside the ring. The contents of the capsule are granules and powder is white or almost white; allowed the formation of conglomerates, easily crumbling with light pressure.
One capsule Ingavirin contains: active substance: pentanedioic imidazolylethanamide (vitaglutam) in terms of 100% substance - 30.00 mg or 90.00 mg; excipients: lactose monohydrate, potato starch, colloidal silicon dioxide (aerosil), magnesium stearate; hard gelatin capsules: for a dosage of 30 mg - titanium dioxide E 171, diamond black dye E 151, blue patent dye E 131, crimson dye [Ponceau 4 R] E 124, azorubine dye E 122, gelatin; for a dosage of 90 mg - titanium dioxide E 171, crimson dye [Ponceau 4 R] E 124, dye azorubine E 122, quinoline dye yellow E 104, gelatin; logo ink composition: shellac, propylene glycol E 1520, titanium dioxide E 171.
Antiviral drug Ingavirin. Preclinical and clinical studies have shown the effectiveness of the drug Ingavirin against influenza viruses of type A (A (H1N1), including “pig” A (H1N1) pdm09, A (H3N2), A (H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: metapneumovirus, enteroviruses, including Coxsackie virus and rhino virus.
Ingavirin helps accelerate elimination of viruses, reduces the duration of the disease, and reduces the risk of complications. The mechanism of action is realized at the level of infected cells due to the stimulation of innate immunity factors suppressed by viral proteins.
In experimental studies, in particular, it was shown that the drug Ingavirin increases the expression of the first type of IFNAR interferon receptor on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to signals of endogenous interferon. The process is accompanied by activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It was shown that under conditions of infection, the drug Ingavirin stimulates the production of the antiviral effector protein MxA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication.
The drug Ingavirin causes an increase in the content of interferon in the blood to a physiological norm, stimulates and normalizes the decreased β-interferon-producing ability of blood leukocytes, and stimulates the β-interferon-producing ability of leukocytes. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells with high killer activity against virus-infected cells.
The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-β), interleukins (IL-1? And IL-6), and a decrease in the activity of myeloperoxidase. In experimental studies, it was shown that the combined use of the drug with antibiotics increases the effectiveness of therapy on a model of bacterial sepsis, including that caused by penicillin-resistant staphylococcus strains. Conducted experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug Ingavirin. According to the parameters of acute toxicity, Ingavirin belongs to the 4th toxicity class -
“Low toxic substances” (in determining the LD50 in experiments on acute toxicity, lethal doses of the drug Ingavirin could not be determined). The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a locally irritating effect. The drug does not affect reproductive function, does not have embryotoxic and teratogenic effects.
Suction and distribution. In an experiment using a radioactive label, it was found: the drug quickly enters the bloodstream from the gastrointestinal tract. Evenly distributed throughout the internal organs. The maximum concentration in the blood, blood plasma and most organs is achieved 30 minutes after administration of the drug. The AUC values (the area under the pharmacokinetic curve “concentration - time”) of the kidneys, liver, and lungs are slightly higher than the blood AUC (43.77 μg.h / g).
AUC values for the spleen, adrenal glands, lymph nodes and thymus below the blood AUC. MRT (median drug Ingavirin retention time) in the blood is 37.2 hours. With the course of taking the drug Ingavirin once a day, it accumulates in the internal organs and tissues. In this case, the qualitative characteristics of the pharmacokinetic curves after each administration of the drug were identical: a rapid increase in the concentration of the drug after each administration 0.5-1 hours after administration and then a slow decrease by 24 hours. Metabolism.
The drug is not metabolized in the body and is excreted unchanged. Breeding. The main process of excretion occurs within 24 hours. During this period, 80% of the dose taken is excreted: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. Of these, 77% is excreted through the intestines and 23% through the kidneys.
Side effects Ingavirin:
Allergic reactions for Ingavirin (rare). If any of the side effects indicated in the instructions are aggravated or you notice any other side effects not listed in the instructions, inform your doctor.
Features of the sale Supplied without a prescription Special conditions The simultaneous use of other antiviral drugs is not recommended without first consulting a doctor. Influence on the ability to drive vehicles, mechanisms Not studied, however, given the mechanism of action and the profile of adverse reactions, we can assume that the drug does not affect the ability to drive vehicles, mechanisms.
Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in adults and children from 3 years.
Innovative drug for the treatment and prevention of influenza A, B, viral respiratory infections
Hypersensitivity to the active substance or any other component of the drug Ingavirin. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Pregnancy. The period of breastfeeding.
Children's age up to 3 years. Use during pregnancy and during breastfeeding The use of the drug during pregnancy has not been studied.
The use of the drug during lactation has not been studied, therefore, if necessary, the use of the drug during lactation should stop breastfeeding. Drug interaction Ingavirin
The drug interaction of the drug Ingavirin is not described.
Inside Ingavirin. Regardless of the meal. In children from 3 to 6 years old who have difficulty swallowing the capsule, it is allowed to dilute the contents of the capsule in water or apple juice. To do this, gently open the capsule above the container with a small amount (50-70 ml) of boiled water or apple juice at room temperature, pour the contents of the capsule into water or juice, mix the mixture for 20 seconds and drink it whole. Sugar added. The mixture should be prepared immediately before administration; ready mix is not subject to storage. For the treatment and prevention of influenza and acute respiratory viral infections, adults are prescribed 90 mg once a day, children from 7 years old - 60 mg once a day, children from 3 to 6 years old - 30 mg once a day. The duration of treatment for influenza and acute respiratory viral infections in adults and children from 7 years old is 5-7 days (depending on the severity of the condition). The duration of treatment for influenza and acute respiratory viral infections in children from 3 to 6 years is 5 days. Taking the drug begins with the onset of the first symptoms of the disease, preferably not later than 2 days from the onset of the disease. For the prevention of influenza and acute respiratory viral infections after contact with sick people, adults and children from 7 years of age are prescribed the drug Ingavirin for 7 days, children from 3 to 6 years old - for 5 days. If after 5 days of treatment no improvement occurs or the symptoms worsen, or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the method of use Ingavirin and at the doses indicated in the instructions.
Overdose Ingavirin:Cases of overdose of the drug Ingavirin to date have not been reported.
|Active substance||Pentanedioic acid imidazolyl ethanamide|
|Pills in 1 package||10|
|Country of origin||Russia|
|Expiration Date (in months)||Always fresh|